{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:18:28Z","timestamp":1773839908059,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T00:00:00Z","timestamp":1410134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Genotype 2 hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) accounts for up to 30% of chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infections in Japan. The standard of care for patients with genotype 2 <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> \u2013 peginterferon and ribavirin for 24\u00a0weeks \u2013 is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a phase 3, open\u2010label study to assess the efficacy and safety of an all\u2010oral combination of the <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>5B polymerase inhibitor sofosbuvir and ribavirin in patients with chronic genotype 2 <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection in Japan. We enrolled 90 treatment\u2010na\u00efve and 63 previously treated patients at 20 sites in Japan. All patients received sofosbuvir 400\u00a0mg plus ribavirin (weight\u2010based dosing) for 12\u00a0weeks. The primary endpoint was sustained virologic response at 12\u00a0weeks after therapy (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12). Of the 153 patients enrolled and treated, 60% had <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 2a, 11% had cirrhosis, and 22% were over the aged 65 or older. Overall, 148 patients (97%) achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12. Of the 90 treatment\u2010na\u00efve patients, 88 (98%) achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12, and of the 63 previously treated patients, 60 (95%) achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12. The rate of <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 was 94% in patients with cirrhosis and in those aged 65 and older. No patients discontinued study treatment due to adverse events. The most common adverse events were nasopharyngitis, anaemia and headache. Twelve weeks of sofosbuvir and ribavirin resulted in high rates of <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 in treatment\u2010na\u00efve and previously treated patients with chronic genotype 2 <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection. The treatment was safe and well tolerated by patients, including the elderly and those with cirrhosis.<\/jats:p>","DOI":"10.1111\/jvh.12312","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T05:05:06Z","timestamp":1410152706000},"page":"762-768","source":"Crossref","is-referenced-by-count":176,"title":["Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV<\/scp> infection: an open\u2010label, phase 3 trial"],"prefix":"10.1111","volume":"21","author":[{"given":"Masao","family":"Omata","sequence":"first","affiliation":[{"name":"Yamanashi Prefectural Hospital Organization Yamanashi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Nishiguchi","sequence":"additional","affiliation":[{"name":"Hyogo College of Medicine Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Yamagata University Yamagata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Yamanashi Prefectural Hospital Organization Yamanashi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[{"name":"Musashino Red Cross Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusao","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Okayama University Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Ogaki Municipal Hospital Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[{"name":"Chiba University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Nirei","sequence":"additional","affiliation":[{"name":"Nihon University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Genda","sequence":"additional","affiliation":[{"name":"Juntendo University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[{"name":"Shinshu University Nagano Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[{"name":"Osaka University Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Hokkaido University Hokkaido Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nishigaki","sequence":"additional","affiliation":[{"name":"Gifu Municipal Hospital Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"Nakane","sequence":"additional","affiliation":[{"name":"Akita City Hospital Akita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Toda","sequence":"additional","affiliation":[{"name":"Mitsui Memorial Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[{"name":"Kurume University Kurume Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Yanase","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Hino","sequence":"additional","affiliation":[{"name":"Kawasaki Medical School Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Gao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly L.","family":"Garrison","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas","family":"Dvory\u2010Sobol","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masa","family":"Omote","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Brainard","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Knox","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Symonds","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagasaki Medical Center Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000252782"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000076640"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087260"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268814000478"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2009.00634.x"},{"key":"e_1_2_7_8_1","volume-title":"Sovaldi (sofosbuvir) Tablets: US Prescribing Information"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_2_7_12_1","unstructured":"KirbyB GordiT SymondsWT KearneyBP MathiasA.Population pharmacokinetics of sofosbuvir and its major metabolite (GS\u2010331007) in healthy and HCV\u2010infected adult subjects. AASLD Annual Meeting2013."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1750-7"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01182.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23691"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12312","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.12312","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:39:50Z","timestamp":1696243190000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,8]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1111\/jvh.12312"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12312","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,8]]}}}